CryoPort and American Biologistics Agree to Expand Cryogenic Shipping on Global Basis

BREA, CA -- (MARKET WIRE) -- 04/30/07 -- CryoPort, Inc. (PINKSHEETS: CYRX) announced today that it has finalized the terms of a business alliance agreement with American Biologistics Company, an affiliate of Commodity Sourcing Group ("CSG").

On January 3, 2007, CryoPort and CSG signed a letter of intent to establish a logistics platform designed to launch the CryoPort Express® One-Way Shipper System. On March 13, 2007, the parties furthered that initial effort by entering into a business alliance agreement that set the stage for an affiliate of CSG to obtain a licensing agreement with a royalty provision for the on-going use of CryoPort's technology. Today's announcement finalizes the agreement and allows CryoPort to focus on its expertise in developing, manufacturing and marketing its line of cryogenic shipping products and American Biologistics to implement its logistical support throughout the supply chain.

CryoPort's CEO, Mr. Peter Berry, commented, "CryoPort and CSG have been working on the development of a strategic partnership for several months. Through this alliance, I believe that CryoPort will be in a position to bring its products to market on an expedited basis. CryoPort develops, markets and manufactures cryogenic shipping systems. American Biologistics will strategically complement the needs of CryoPort. I believe that this business alliance sets the stage for the temperature sensitive shipping industry to be changed via the introduction of a 'disruptive' technology implemented through a unique logistics platform."

Additional information on CryoPort, including a downloadable Investor Fact Sheet, can be found at

About CryoPort, Inc.

CryoPort ( develops leading edge, proprietary, technology driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical sectors. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery components that make up the foundation of the biopharmaceutical and biotechnology industries.


This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Investor Relations:
First Capital Investors, Inc.
Email Contact